A new drug, a monoclonal antibody known as enoblituzumab, is safe in men with aggressive prostate cancer and may induce clinical activity against cancer throughout the body, according to a phase 2 study led by investigators at the Johns Hopkins Kimme
Taiwan: A recent study in CMAJ (Canadian Medical Association Journal) has highlighted the importance of the prudent use of computed tomography (CT) in the pediatric population. The study showed that.
A team led by a Penn State researcher has developed a medical sensor that can transform from rigid to soft to accommodate changing structural needs and can heal its own normal wear-and-tear.